Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Brainsway ( (BWAY) ) is now available.
At the Annual General Meeting held on September 11, 2025, Brainsway Ltd. successfully passed all proposed resolutions with the necessary majority of shareholder votes. Key decisions included the appointment of Kost Forer Gabbay & Kasierer as the independent auditors for 2025 and the re-election of several directors to the Board. Additionally, the meeting approved updates to the compensation package for CEO Hadar Levy, reflecting the company’s commitment to aligning executive incentives with its strategic goals.
The most recent analyst rating on (BWAY) stock is a Buy with a $19.00 price target. To see the full list of analyst forecasts on Brainsway stock, see the BWAY Stock Forecast page.
Spark’s Take on BWAY Stock
According to Spark, TipRanks’ AI Analyst, BWAY is a Outperform.
Brainsway’s overall stock score is driven by its strong financial performance and positive earnings call, highlighting significant revenue growth and strategic investments. However, the high valuation and technical indicators suggesting overbought conditions temper the score.
To see Spark’s full report on BWAY stock, click here.
More about Brainsway
Brainsway Ltd. operates in the medical technology industry, specializing in the development and provision of advanced non-invasive neurostimulation treatments for mental health disorders. The company focuses on delivering innovative solutions to address conditions such as depression and obsessive-compulsive disorder, leveraging its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology.
Average Trading Volume: 63,288
Technical Sentiment Signal: Buy
Current Market Cap: $301.5M
For an in-depth examination of BWAY stock, go to TipRanks’ Overview page.